Cardiol Therapeutics Inc. (TSX:CRDL,OTC:CRTPF) was featured in an article by Technical420 which covered the shift away from cannabis cultivation into a marketing, science and quality standards-based cannabis market. The report also discussed Cardiol’s efforts in meeting new industry standards. According to the article, the cannabis industry is shifting away from large cultivation facilities focused on producing premium cannabis towards a standards-based market to one based in science. The life science industry is fueling the shift as they capitalize on the growing CBD market.

Cardiol is a biotechnology company focused on developing proprietary formulas to treat some of the most life-threatening diseases. The company has established a proprietary supply-chain to produce pharmaceutically pure CBD at a multi-metric tonne scale through its partnerships with Noramco and Dalton Pharma. Cardiol’s manufacturing process for producing pharmaceutical CBD is also efficient and cost-effective, setting the company apart from its peers. The company’s partnerships and distribution agreements in Europe and Latine America will allow them to capitalize on the global CBD market.


According to the article, Cardiol is poised to generate revenue in the first half of 2019 through the commercial launch of its CardiolRx pharmaceutical CBD brand in Canada’s medical cannabis market. CardiolRx is a Health Canada-certified CBD product with a greater than 99.5 percent purity. Cardiol is also developing a targeted therapy for heart failure, which is one of the largest medical markets in the world. The successful commercialization of the company’s drug candidates for heart failure would be a significant catalyst for Cardiol. The company is focused on advancing its clinical trial programs for heart disease under a management team that has experience in developing companies in the medical space.

To read the full article, click here.

Click here to connect with Cardiol Therapeutics (TSX:CRDL) for an investor presentation. 

Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.

The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.

Keep reading... Show less

A planned business merger between two leading cannabis producers hit a small delay this week as a critical vote got moved.

Meanwhile, a cannabis retail operator elected to celebrate 420 by auctioning a cannabis-themed digital art piece using blockchain technology.

Keep reading... Show less

Partnerships with Minardi Law , Minorities for Medical Marijuana, CultivatED, and the Georgia Justice Project will include clinics and virtual events across Florida , Georgia , and Massachusetts

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today a series of expungment clinics located throughout south and central Florida as well as virtual events in Georgia and Massachusetts . The clinics are part of the Company’s celebration of the 50 th anniversary of 420.

Keep reading... Show less

Seth Rogen’s New Cannabis Brand are Now Available at Apothecarium Dispensaries in San Francisco , Berkeley and Capitola

The Apothecarium is offering cannabis from Houseplant, the cannabis lifestyle brand founded by Seth Rogen and Evan Goldberg at its five California dispensaries. The Apothecarium has three San Francisco locations (Castro, SOMA and Marina ) and one each in Berkeley and Capitola (outside of Santa Cruz ).

Keep reading... Show less